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Amyotrophic lateral sclerosis (ALS; MND, motor neuron disease) is a debilitating
neurodegenerative disease affecting 4.5 per 100,000 people per year around the world.
There is currently no cure for this disease, and its causes are relatively unknown.
Diagnosis is based on a battery of clinical tests up to a year after symptom onset, with no
robust markers of diagnosis or disease progression currently identified. A major thrust
of current research is to identify potential non-invasive markers (“biomarkers”) in body
fluids such as blood and/or cerebrospinal fluid (CSF) to use for diagnostic or prognostic
purposes. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), are found at
detectable and stable levels in blood and other bodily fluids. Specific ncRNAs can vary
in levels between ALS patients and non-ALS controls without the disease. In this review,
we will provide an overview of early findings, demonstrate the potential of this new class
as biomarkers, and discuss future challenges and opportunities taking this forward to
help patients with ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is themost prevalent adult onset form ofmotor neuron disease.
As a result of progressive death of motor neurons in the primary motor cortex, brainstem and
spinal cord, there is atrophy of the muscles that are innervated by these neurons. This results in
muscle weakness and paralysis with death usually occurring within 3–5 years. Over the last decade,
significant progress has been made in identifying the genes responsible for familial cases of ALS
(fALS). Of these, the most frequently mutated genes are chromosome 9 open reading frame 72
(C9orf72), superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TARDBP; TDP-43),
and FUS RNA binding protein (FUS), accounting for over 70% of fALS cases (1). Nevertheless,
fALS constitutes approximately 10% of all cases, with the genetic underpinnings of sporadic ALS
(sALS) mostly unknown, though C9orf72 is known to account for 5% of sALS cases.
The lack of a common cause has resulted in difficulties not only in timely disease diagnosis
resulting in delay of treatment, but in developing drugs and treatments for the disease. Thus,
identifying useful biomarkers as tools for early diagnosis, for determining subgroups in relation
to pathogenesis and/or phenotype, and as indicators of treatment response, are urgently required.
Development of biomarkers that are minimally invasive to obtain, simple to undertake, and time
efficient are key and those derived from biofluids, such as blood, are well suited for this. Further, it
is not necessary for the biomarkers to underlie the pathology of the disease if it correlates strongly
and specifically to the disease. Indeed, this is more difficult to assess in diseases such as ALS where
the underlying molecular causes of pathology is unknown or unclear.
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One class of molecules increasingly investigated as potential
biomarkers are short ncRNA species (those under 100
nucleotides long), which include tRNA, rRNA, piwi-RNA
(piRNA), and microRNA (miRNA). MiRNA have been the main
focus of most studies to date, driven by a good understanding
of their biogenesis and function, an ease in profiling their
expression with a range of techniques including microarray,
RNA-seq, and RT-qPCR, a relatively simple structure, increased
stability from RNase degradation and freeze-thaw cycles, and a
presence in a range of biofluids including blood, cerebrospinal
fluid (CSF), and urine (2, 3). To date, a number of studies
have shown that miRNAs are differentially expressed in ALS
patients when compared to controls in a variety of biofluids,
including CSF, and in the blood-derived components plasma
and serum (4–18) (summarized in Table 1). This review
will aim to present recent work identifying miRNA-based
biomarkers in biofluids, the possibility of using other ncRNA
as biomarkers, and the next steps required to move this into a
clinical setting.
EXISTING CIRCULATING RNA
BIOMARKERS FOR ALS
Serum-Based Biomarkers
Freischmidt and colleagues have undertaken a number of
studies to identify potential miRNA-based biomarkers in the
ALS patient serum (4, 6, 8). Their first study selected ten
miRNAs previously identified to regulate the ALS-related gene
TARDPB and found five miRNAs were differentially expressed
in serum of sALS patients (4). Their later study focused on
miRNA expression in serum from fALS patients using Affymetrix
miRNA array chips, and found downregulation of a set of 30
potential miRNA biomarkers for the disease [Table 1; 3]. Four
miRNA were selected based on their false discovery rate (FDR)-
adjusted p-value (MIR1915-3p, MIR3665, MIR4530, MIR4745-
5p) and their downregulation validated with RT-qPCR in the
fALS patients, and all but MIR1915-3p were further observed to
be downregulated in sALS patients. While increased variability
was observed in sALS patients, this suggested that there may
be similarities in the miRNA profile between the two groups.
Curiously, these three miRNAs (MIR3665, MIR4530, MIR4745-
5p) were found not to be differentially expressed in their most
recent study using sALS patients, which described onlyMIR1234-
3p and MIR1825 as being downregulated (8). An interesting
aspect of their 2014 study was investigating miRNA expression
in non-symptomatic patients who had ALS-related genetic
mutations, but predicted to present disease symptoms within the
next 20 years. These predicted pre-symptomatic carriers shared
91.7% of the downregulated miRNA of symptomatic patients,
although to a lesser dysregulation. This suggests that these
biomarkers may be present before symptoms and could be used
to identify potential ALS cases. Furthermore, considering there
were differences between pre-symptomatic and symptomatic
patients in the degree of dysregulation, this may suggest that
these biomarkers could change with time. However, further work
would be needed to determine this and if it would apply to
sALS cases along with whether these biomarkers are specific
to ALS itself.
Other studies have also identified potential biomarkers
that may be differentially expressed in serum from ALS
patients. The upregulation of MIR143-3p and MIR206, and
the downregulation of MIR374B-5p were observed in 23 sALS
patients and were further validated in an additional 27 sALS
patients (13). Of these, 22 samples were in a longitudinal
study and MIR143-3p and MIR374B-5p both became more
dysregulated, suggesting a link to disease progression, though
MIR206 remained stable for at least 3 months later. Another
study using patient serum also found MIR206 upregulation in
ALS patients along with MIR106b, differences that were reflected
in a SOD1-G93A mouse model of ALS (7). MIR206, described
as a myoMiR due to its high abundance in skeletal muscle
tissue, is one of the few miRNA biomarkers identified across
multiple studies, including those described below in serum and
plasma (11, 12). The working hypothesis has been that as a
result of muscle death, MIR206 is released from the muscle fibers
and into the blood stream as a waste product (19). However,
MIR206 has been identified as a blood-based biomarker for
other muscle-related diseases and therefore not specific to ALS
(20, 21). Nonetheless, it could play an important role in helping
to identify ALS patients if used in conjunction with other
biomarkers to help distinguish from ALS-like conditions. Lastly,
one study has investigated the exosomes present in serum, and
investigated a single miRNA (MIR27A-3p) based on the research
group’s previous work with myoblast exosomes (18). However,
the normalization to MIR16-5p may limit the interpretation
of this data as it has been shown to be dysregulated in ALS
(15, 22) and no evidence was shown that MIR16-5p was stable.
Nonetheless, with a fuller investigation, identifying dysregulated
miRNA present in exosomes in ALS may provide clues as to
the source, destination, and thus function of circulating miRNA
in ALS.
Plasma-Based Biomarkers
Two studies have investigated biomarkers in sALS patients using
plasma; the portion of blood which contains clotting factors.
Using microarray analysis followed by RT-qPCR, Takahashi
et al. (9) found significant upregulation of MIR4649-5p and
downregulation ofMIR4299 in ALS patients compared to healthy
controls. Interestingly, this study incorporated a follow up
analysis of the expression of miRNAs in seven of the patients,
including one patient 24 months later. However, no significant
change in the expression of any of the miRNAs were found,
although there was a trend for an increase of MIR663b over
time. Similarly, in another study, while MIR424 and MIR206
were found to be overexpressed in plasma of sALS patients, they
did not show significant changes over 6 and 12 months in a
cohort of sALS patients (11). This lack of change in MIR206
over time is consistent with the above results of Waller et al.
(13). This suggests that for these miRNA, their expression levels
are not correlated with disease progression and changes in the
patient condition. This may mean that they may only be suitable
as diagnostic markers and not useful in tracking treatment
responses in disease.
Frontiers in Neurology | www.frontiersin.org 2 March 2019 | Volume 10 | Article 186
Joilin et al. MirocRNAs as Biomarkers of ALS
T
A
B
L
E
1
|
C
irc
u
la
tin
g
m
iR
N
A
-b
a
se
d
b
io
m
a
rk
e
rs
fo
u
n
d
to
b
e
d
iff
e
re
n
tia
lly
e
xp
re
ss
e
d
in
b
io
flu
id
s.
A
u
th
o
rs
A
L
S
ty
p
e
n
V
a
li
d
a
te
d
c
h
a
n
g
e
s
C
o
n
tr
o
ls
R
N
A
e
x
tr
a
c
ti
o
n
P
ro
fi
li
n
g
te
c
h
n
iq
u
e
R
T-
q
P
C
R
v
a
li
d
a
ti
o
n
R
T-
q
P
C
R
n
o
rm
a
li
z
a
ti
o
n
In
c
re
a
s
e
D
e
c
re
a
s
e
S
e
ru
m
F
re
is
c
h
m
id
t
e
t
a
l.
(4
)
S
p
o
ra
d
ic
2
2
M
IR
1
4
3
-5
p
M
IR
5
7
4
-5
p
M
IR
1
3
2
-5
p
M
IR
1
3
2
-3
p
M
IR
1
4
3
-3
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
m
iR
N
e
a
sy
M
in
i
-
N
c
o
d
e
V
IL
O
E
X
P
R
E
S
S
S
Y
B
R
G
re
e
n
E
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
D
e
F
e
lic
e
e
t
a
l.
(5
)
S
p
o
ra
d
ic
7
2
-
M
IR
3
3
8
-3
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
Tr
iz
o
l
-
m
iS
c
rip
t
R
T-
q
P
C
R
L
E
T
7
A
F
re
is
c
h
m
id
t
e
t
a
l.
( 6
)
F
a
m
ili
a
l
2
2
-
M
IR
1
9
1
5
-3
p
M
IR
3
6
6
5
M
IR
4
5
3
0
M
IR
4
7
4
5
-5
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
Q
IA
zo
la
n
d
m
iR
N
e
a
sy
M
in
i
A
ff
ym
e
tr
ix
G
e
n
e
C
h
ip
3
.0
A
rr
a
y
m
iS
c
rip
t
R
T-
q
P
C
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
S
p
o
ra
d
ic
1
4
-
M
IR
3
6
6
5
M
IR
4
5
3
0
M
IR
4
7
4
5
-5
p
To
iv
o
n
e
n
e
t
a
l.
( 7
)
-
1
2
M
IR
1
0
6
B
M
IR
2
0
6
-
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
N
o
rg
e
n
To
ta
l
R
N
A
A
ff
ym
e
tr
ix
G
e
n
e
C
h
ip
2
.0
A
rr
a
y
Ta
q
M
a
n
m
iR
N
A
R
T-
q
P
C
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
F
re
is
c
h
m
id
t
e
t
a
l.
(8
)
S
p
o
ra
d
ic
1
8
-
M
IR
1
2
3
4
-3
p
M
IR
1
8
2
5
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
/
A
lz
h
e
im
e
r’s
/
H
u
n
tin
g
to
n
’s
Q
IA
zo
la
n
d
m
iR
N
e
a
sy
M
in
i
A
ff
ym
e
tr
ix
G
e
n
e
C
h
ip
3
.0
A
rr
a
y
m
iS
c
rip
t
R
T-
q
P
C
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
W
a
lle
r
e
t
a
l.
( 1
3
)
S
p
o
ra
d
ic
5
0
M
IR
1
4
3
-3
p
M
IR
2
0
6
M
IR
3
7
4
B
-5
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
/
d
is
e
a
se
m
im
ic
s
N
o
rg
e
n
C
irc
u
la
tin
g
N
u
c
le
ic
A
c
id
Is
o
la
tio
n
Ta
q
M
a
n
L
o
w
D
e
n
si
ty
R
T-
q
P
C
R
a
rr
a
ys
m
iS
c
rip
t
R
T-
q
P
C
R
M
IR
1
7
-5
p
M
IR
2
4
M
IR
2
2
3
-3
p
M
a
ta
m
a
la
e
t
a
l.
( 1
6
)
S
p
o
ra
d
ic
2
0
M
IR
1
2
4
9
-3
p
M
IR
1
4
2
-3
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
Tr
iz
o
lL
S
a
n
d
m
iR
N
e
a
sy
S
e
ru
m
/P
la
sm
a
Ill
u
m
in
a
Tr
u
S
e
q
S
m
a
ll
R
N
A
o
n
Ill
u
m
in
a
M
iS
e
q
Ta
q
M
a
n
m
iR
N
A
R
T-
q
P
C
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
R
a
h
e
ja
e
t
a
l.
(1
7
)
S
p
o
ra
d
ic
/F
a
m
ili
a
l
2
3
S
c
re
e
n
o
n
ly
S
c
re
e
n
o
n
ly
H
e
a
lth
y
c
o
n
tr
o
ls
m
iR
c
u
ry
m
iR
N
A
L
N
A
R
T-
q
P
C
R
a
rr
a
ys
-
-
X
u
e
t
a
l.
( 1
8
)
-
1
0
-
M
IR
2
7
A
-3
p
H
e
a
lth
y
c
o
n
tr
o
ls
Tr
iz
o
lo
r
m
iR
N
e
a
sy
M
ic
ro
-
m
iD
E
T
E
C
T
A
Tr
a
c
k
m
iR
N
A
R
T-
q
P
C
R
o
r
Ta
q
M
a
n
m
iR
N
A
R
T-
q
P
C
R
M
IR
1
6
-5
p
P
la
sm
a
Ta
ka
h
a
sh
ie
t
a
l.
(9
)
S
p
o
ra
d
ic
4
8
M
IR
4
6
4
9
-5
p
M
IR
4
2
9
9
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
m
iR
N
e
a
sy
S
e
ru
m
/P
la
sm
a
3
D
-G
e
n
e
H
u
m
a
n
m
iR
N
A
o
lig
o
c
h
ip
m
iS
c
rip
t
R
T-
q
P
C
R
M
IR
4
5
1
6
(C
o
n
ti
n
u
e
d
)
Frontiers in Neurology | www.frontiersin.org 3 March 2019 | Volume 10 | Article 186
Joilin et al. MirocRNAs as Biomarkers of ALS
T
A
B
L
E
1
|
C
o
n
tin
u
e
d A
u
th
o
rs
A
L
S
ty
p
e
n
V
a
li
d
a
te
d
c
h
a
n
g
e
s
C
o
n
tr
o
ls
R
N
A
e
x
tr
a
c
ti
o
n
P
ro
fi
li
n
g
te
c
h
n
iq
u
e
R
T-
q
P
C
R
v
a
li
d
a
ti
o
n
R
T-
q
P
C
R
n
o
rm
a
li
z
a
ti
o
n
In
c
re
a
s
e
D
e
c
re
a
s
e
d
e
A
n
d
ra
d
e
e
t
a
l.
(1
1
)
S
p
o
ra
d
ic
3
9
M
IR
4
5
4
M
IR
2
0
6
-
A
g
e
d
m
a
tc
h
h
e
a
lth
y
c
o
n
tr
o
l
m
iR
V
a
n
a
P
A
R
IS
A
ff
ym
e
tr
ix
G
e
n
e
C
h
ip
a
rr
a
y
(o
n
m
u
sc
le
)
Ta
q
M
a
n
m
iR
N
A
R
T-
q
P
C
R
M
IR
1
6
-5
p
S
h
e
in
e
rm
a
n
e
t
a
l.
(1
2
)
-
5
0
M
IR
2
0
6
/M
IR
3
3
8
-3
p
M
IR
9
/M
IR
1
2
9
-3
p
M
IR
3
3
5
-5
p
/M
IR
3
3
8
-3
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
Tr
iz
o
la
n
d
A
m
b
io
n
G
la
ss
F
ib
e
r
C
o
lu
m
n
s
L
ite
ra
tu
re
se
a
rc
h
Ta
q
M
a
n
m
iR
N
A
R
T-
q
P
C
R
-
C
e
re
b
ro
sp
in
a
l
F
lu
id
F
re
is
c
h
m
id
t
e
t
a
l.
( 4
)
S
p
o
ra
d
ic
2
2
M
IR
1
4
3
-5
p
M
IR
1
3
2
-5
p
M
IR
1
3
2
-3
p
M
IR
1
4
3
-3
p
L
E
T
7
B
-5
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
m
iR
N
e
a
sy
M
in
i
-
N
c
o
d
e
V
IL
O
E
X
P
R
E
S
S
S
Y
B
R
G
re
e
n
E
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
D
e
F
e
lic
e
e
t
a
l.
( 5
)
S
p
o
ra
d
ic
7
2
M
IR
3
3
8
-3
p
-
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
Tr
iz
o
l
-
m
iS
c
rip
t
R
T-
q
P
C
R
M
IR
2
4
B
e
n
ig
n
ie
t
a
l.
(1
0
)
S
p
o
ra
d
ic
2
4
L
E
T
7
A
-5
p
L
E
T
7
B
-5
p
L
E
T
7
F
-5
p
M
IR
1
5
B
-5
p
M
IR
2
1
-5
p
M
IR
1
9
5
-5
p
M
IR
1
4
8
A
-3
p
M
IR
1
8
1
A
-5
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
m
iR
N
e
a
sy
M
in
i
H
u
m
a
n
m
iF
in
d
e
r
3
8
4
H
C
m
iR
N
A
P
C
R
a
rr
a
y
S
Y
B
R
G
re
e
n
R
T-
q
P
C
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
M
IR
6
0
8
M
IR
3
2
8
-3
p
W
a
lle
r
e
t
a
l.
( 1
4
)
S
p
o
ra
d
ic
3
2
S
c
re
e
n
o
n
ly
S
c
re
e
n
o
n
ly
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
/d
is
e
a
se
m
im
ic
s
m
iR
V
a
n
a
P
A
R
IS
Ill
u
m
in
a
Tr
u
S
e
q
S
m
a
ll
R
N
A
o
n
Ill
u
m
in
a
H
iS
c
a
n
S
q
m
iS
c
rip
t
II
R
T-
q
P
C
R
S
p
ik
e
d
in
c
e
l-
M
IR
3
9
-3
p
M
IR
3
0
A
-5
p
W
h
o
le
B
lo
o
d
L
ig
u
o
ri
e
t
a
l.
(1
5
)
S
p
o
ra
d
ic
5
6
-
L
E
T
7
A
-5
p
L
E
T
7
D
-5
p
L
E
T
7
F
-5
p
L
E
T
7
G
-5
p
L
E
T
7
I-
5
p
M
IR
1
5
A
-5
p
M
IR
1
5
B
-5
p
M
IR
1
5
1
A
-5
p
M
IR
1
5
1
B
M
IR
1
6
-5
p
M
IR
2
2
-3
p
M
IR
2
3
A
-3
p
M
IR
2
6
A
-5
p
M
IR
2
6
B
-5
p
M
IR
2
7
B
-3
p
M
IR
2
8
-3
p
M
IR
3
0
B
-5
p
(C
o
n
ti
n
u
e
d
)
Frontiers in Neurology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 186
Joilin et al. MirocRNAs as Biomarkers of ALS
T
A
B
L
E
1
|
C
o
n
tin
u
e
d A
u
th
o
rs
A
L
S
ty
p
e
n
V
a
li
d
a
te
d
c
h
a
n
g
e
s
C
o
n
tr
o
ls
R
N
A
e
x
tr
a
c
ti
o
n
P
ro
fi
li
n
g
te
c
h
n
iq
u
e
R
T-
q
P
C
R
v
a
li
d
a
ti
o
n
R
T-
q
P
C
R
n
o
rm
a
li
z
a
ti
o
n
In
c
re
a
s
e
D
e
c
re
a
s
e
M
IR
3
0
C
-5
p
M
IR
9
3
-5
p
M
IR
1
0
3
A
-3
p
M
IR
1
0
6
B
-3
p
M
IR
1
2
8
-3
p
M
IR
1
3
0
A
-3
p
M
IR
1
3
0
B
-3
p
M
IR
1
4
4
-5
p
M
IR
1
4
8
A
-3
p
M
IR
1
4
8
B
-3
p
M
IR
1
8
2
-5
p
M
IR
1
8
3
-5
p
M
IR
1
8
6
-5
p
M
IR
2
2
1
-3
p
M
IR
2
2
3
-3
p
M
IR
3
4
2
-3
p
M
IR
4
2
5
-5
p
M
IR
4
5
1
A
M
IR
5
3
2
-5
p
M
IR
5
5
0
A
-3
p
M
IR
5
8
4
-5
p
A
g
e
-m
a
tc
h
e
d
h
e
a
lth
y
c
o
n
tr
o
ls
P
A
X
g
e
n
e
B
lo
o
d
R
N
A
Ill
u
m
in
a
Tr
u
S
e
q
S
m
a
ll
R
N
A
o
n
Ill
u
m
in
a
H
iS
e
q
2
5
0
0
Ta
q
M
a
n
A
d
va
n
c
e
d
m
iR
N
A
R
T-
q
P
C
R
M
IR
4
8
4
T
h
o
s
e
m
iR
N
A
u
n
d
e
rl
in
e
d
s
h
o
w
c
o
n
s
is
te
n
t
d
ir
e
c
ti
o
n
a
lc
h
a
n
g
e
s
b
e
tw
e
e
n
c
o
n
tr
o
la
n
d
A
L
S
c
a
s
e
s
w
h
ile
th
o
s
e
in
b
o
ld
s
h
o
w
c
o
n
tr
a
s
ti
n
g
d
ir
e
c
ti
o
n
a
lc
h
a
n
g
e
s
b
e
tw
e
e
n
c
o
n
tr
o
la
n
d
A
L
S
c
a
s
e
s
.
Frontiers in Neurology | www.frontiersin.org 5 March 2019 | Volume 10 | Article 186
Joilin et al. MirocRNAs as Biomarkers of ALS
Cerebrospinal Fluid-Based Biomarkers
In addition to serum and plasma, differential expression of
ncRNA has also been investigated in CSF. Although CSF is
not as easily obtainable as blood, changes in expression may
potentially be more insightful due to its close proximity to
the central nervous system. Using RT-qPCR, De Felice et al.
(5) not only found MIR338-3p to be over-expressed in serum,
but also in CSF, blood leukocytes, and spinal cord tissue in
ALS patients compared to controls and other patient groups
(including patients with Alzheimer’s and Parkinson’s disease).
In situ hybridization staining of spinal cord tissue post mortem
found that MIR338-3p was localized in the dorsal root gray
matter and overexpressed in ALS patients, suggesting a potential
source of the miRNA. In contrast, Freischmidt et al. (4) used the
biomarkers identified in their serumwork to find out if there were
similar changes in the CSF. While four of those miRNAs were
dysregulated, only MIR143-3p showed a significant correlative
relationship between the serum and CSF, suggesting there is low
correlation in miRNA expression between these two biofluids.
Combined with generally higher concentrations of miRNA in
the serum, the authors concluded that there might be separate
regulatory mechanisms underlying the levels of miRNAs in these
two body compartments. This is supported by other papers
looking into CSF which have shown very little overlap with other
serum studies, but studies that have looked at both within the
same sample groups are limited.
EMERGING THEMES IN ALS BIOMARKER
DISCOVERY
Recently, two main themes are starting to emerge in biomarker
discovery, including in those for ALS. Firstly, it is becoming
evident that seeking to identify singular biomarkers for disease
is unlikely, underscored by the minimal overlap demonstrated
by the above studies. In a study to identify miRNA biomarkers
in CSF, using ratios between the expression of two miRNA as
determined by RT-qPCR increased sensitivity and specificity in
identifying sALS cases compared to using a single miRNA (10).
The study pointed out that the use of more than one miRNA as a
“biomarker signature” is preferable as it reduces the dependency
on variation between individuals. The pairing of the upregulated
MIR181A-5p, with either of their two downregulated miRNA,
MIR21-5p and MIR15B-5p, increased both the sensitivity and
the specificity, with MIR15B-5p increased by 15% on average.
Another study has also used this concept for miRNA present
in serum, using a number of pairs to identify not only
patients with ALS, but other neurological disorders such as
Alzheimer’s disease, frontotemporal dementia, and Parkinson’s
disease (12). Having identified 37 brain- or inflammation-
enriched miRNA, they found the combination of the three
pairs of miRNAs (MIR206/MIR338-3p, MIR9/MIR129-3p, and
MIR335-5p/MIR338-3p) were able to clearly distinguish between
ALS and control patients in their cohort with a sensitivity of 84%
and a specificity of 82%. Furthermore, other paired combinations
were able to differentiate between other neurodegenerative
diseases and ALS. Sheinerman et al. (12) found an 8-fold
increase in MIR206 levels in the plasma of ALS patients when
compared to the controls and this was enough to distinguish ALS
patients from controls by itself. Therefore, on the whole, pairs
of miRNA were able to distinguish between the various diseases
and controls with higher accuracy than could be achieved by an
individual miRNA.
Secondly, recent advances have improved the generation of
high quality libraries from small amounts of starting RNA,
allowing unbiased screening of potential ncRNA biomarkers by
the RNA-seq technique. In one of the first studies, following on
from their work with serum, Waller et al. (14) used RNA-seq
to profile miRNA expression in the CSF of ALS patients. While
they were able to successfully sequence the miRNA and identify
potential candidates, they were unable to confirm those with RT-
qPCR because of technical issues. Nonetheless, it supports the
conclusion of the above studies that differences in miRNA can
be detected in CSF and that CSF could be a source of biomarkers.
More recently, one study has used total blood to screen
for miRNA biomarkers in ALS using RNA-seq (15). Following
identification of 42 differentially expressed miRNA in the
discovery cohort, 38 were validated using RT-qPCR, most
of which have been previously reported in other papers.
Interestingly, seven of the miRNAs (MIR30B-5p, MIR30C-5p,
MIR106B-3p, MIR128-3p, MIR148B-3p, MIR186-5p, MIR342-
3p) were able to distinguish between spinal and bulbar onset,
with decreased expression present for those with spinal onset.
Furthermore, this study also carried out RNA-seq on mRNAs in
the same samples to help identify targets that could be regulated
by the miRNA. The use of total blood, however, limits the
interpretation of these results due to the presence of red blood
cells in the samples and the possibility of variable numbers
of different types of white blood cells between patient and
control groups.
Matamala et al. (16) also utilized RNA-seq for the
identification of ALS biomarkers, but started by profiling
serum samples from transgenic mouse models of ALS, followed
by RT-qPCR validation in human samples. While a number
of miRNAs were found to change in levels between the ALS
model and controls, there was limited cross-validation when
this was taken forward to the human studies. Two miRNA that
did show differences between ALS patients and controls in the
human studies were MIR142-3p and MIR1249-3p. The authors
found that MIR142-3p seemed to correlate negatively with a
decline in clinical disability scale ALSFRS-R in patients, thus
suggesting that this could be used to measure the effect of any
disease-slowing treatment. Further, it was found to potentially
target the expression of the ALS genes TARDBP and C9orf72.
Interestingly, Matamala et al. (16) also briefly described the
detection of non-miRNA ncRNA with their RNA-seq, but did
not state if they were differentially expressed or whether they
were investigated further. As such, there may be a range of
potential biomarkers that have not yet been identified. Indeed,
several other ncRNA species have been detected in serum
including rRNA and tRNA (23–25). These have also been
highlighted as potential biomarkers in diseases other than ALS
in blood (26–29) and other tissues (24, 30–32). To this end, we
are currently using RNA-seq to identify potential biomarkers in
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ALS within the full cohort of ncRNA species, and early results
suggest that we have potential candidates, which include miRNA,
piRNA, and tRNA.
CHALLENGES AND OPPORTUNITIES
Across these studies, there is very little overlap in the miRNA
species as potential biomarkers in the biofluids (see Table 1),
and there are multiple potential reasons for this. Firstly, as
these are mostly from elderly human patients, some of these
patients could have other conditions which could alter the
miRNA composition of the biofluids themselves, thus confound
the detection of ALS-specific biomarkers; careful screening of
patients therefore is required. Further, some of these studies
do not include patients from ALS disease mimics to help
identify ALS-specific markers. This is important as some
biomarkers identified such as MIR206 are not specific to ALS
as described above. Additionally, most of these studies have
been carried out on samples from one population group. As
differences may exist between different populations with the
disease, the lack of cross-validation of changes in miRNA
expression between studies may be reflective of differences in the
patient population, whether that be mediated genetically and/or
environmentally. The number of patients also differ, from 12 to
72 ALS patients, and so the statistical power for some of these
biomarkers is limited.
Alternatively, the causes could be related to the methodology
of the study, from the extraction of the biofluids and RNA,
through to the screening and validation of the miRNA
biomarkers. As seen in Table 1 and Figure 1, a range of different
workflows have been undertaken across all the studies, all of
which may contribute to differences in the changes that are
detected. In addition, some of these factors potentially could
affect the strength of some of these studies. For example, how
the samples were collected and processed may vary. Some of the
studies did not describe their collection procedures, and it is well
known that differences in the centrifugation time post-collection,
speed of centrifugation, and temperature can all affect the quality
and quantity of RNA in the samples (33, 34).
Further, techniques used to normalize the RT-qPCR could
be considered questionable in a number of studies. Due to
the minimal and varied amount of RNA in biofluids, and
the resultant difficulty in quantifying the RNA concentration,
most miRNA RT-qPCR kits used fixed sample volumes instead
of fixed total RNA amounts. Therefore, miRNA RT-qPCR
normalization must control for input RNA, not just for technical
variation, by crucially using a reliable target as a normalizer.
However, no universal normalizer for biomarker work exists,
and identification of a suitable normalizer is a problem across
FIGURE 1 | Summary of the different sample types, techniques, and tools that were used to profile miRNA biomarkers in ALS in the studies presented in this review. As
can be seen alongside Table 1, numerous different combinations of these sample types and tools across the techniques were employed across a number of studies.
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all biofluid biomarker studies (35, 36). Normalizers should be
selected per study from those ncRNA with the most stable
expression in their screen and then validated. Instead, a number
of the above studies have used the synthetic spike-in cel-MIR39B,
but this would only control for technical variation introduced
from RNA extraction onwards, not for the total RNA amount
in the starting volume. Others have used miRNA recommended
as normalizers such as MIR16-5p, but as described above, it has
been shown to be regulated in ALS (15, 22), and also in stress and
in red blood cells (37, 38). Indeed, as some studies did not check
for hemolysis in their samples, the observed changes may be due
to released miRNA from the lysed red blood cells. Taken together,
this underlies why there may be limited cross-validation between
studies and thus careful consideration of identifying objective
normalizers are required.
One question is how do these miRNA-based biomarkers
compare to other biomarkers for ALS? While the properties of
miRNA as biomarkers as described above are ideal, there are
other molecules such as DNA, RNA, protein, and metabolites
that could also be used. One of the most commonly used
biomarkers in ALS is the neurofilament proteins, which form
part of the cytoskeleton of neurons and has been found to
be present in both CSF and serum. Studies have shown that
neurofilaments are able to help with identification of ALS cases
but like MIR206 are not specific to ALS, and rather a measure
of axonal death. As such, it is likely that singular miRNA or
neurofilaments by themselves will not be able to help with ALS
diagnosis or prognosis, but they could form part of any potential
biomarker signature. Therefore, it is likely that an integrative
approach is required, using data on the levels of a number of
ncRNA biomarkers, as has been shown for other diseases (39).
Such approaches include utilizingmultiple biomarkers, including
both miRNA and non-miRNA based biomarkers, and integrating
them into a signature model such as a discriminant model, or
by using ratios of miRNA expression and using them to help
with classification of the disease state, and a number of the
above studies have done this. Together, this may help allow
ALS patients to be specifically identified, not only from healthy
controls but from disease mimics. Therefore, taking this work
forward into larger cohorts of patients is vital to test integrating
these biomarkers together.
Indeed, opportunities from well-designed studies to validate
their biomarkers in separate and larger cohorts could allow for
these biomarkers to be used clinically. Further, these studies have
been designed first and foremost to find biomarkers for ALS
with little attempt to determine the biology underlying these
changes, as presence alone does not infer function. Nonetheless,
considering the wide and varied biological roles of miRNAs,
determining their biological function will be important. Future
studies need to include their source and destination, potentially
by investigating exosomes and their contents and function. These
studies would provide new insights into the mechanisms that
may underlie ALS. Therefore, not only do larger cohorts need
to be screened but proper experimental design needs to be
undertaken to ensure that results are valid and can be used to
progress the field further.
What is ultimately being sought is a set of biomarkers that
are able to help with the diagnosis and prognosis of ALS
patients. Diagnosis and prognosis of patients based on an ncRNA
biomarker could assist with the development of tailored and
targeted treatments to extend or improve patients’ quality of life.
As such, these studies have shown that there is potential here
for ncRNA-based biomarkers to be identified, and with careful
consideration, future work will help to further refine this to
progress this to the clinical setting.
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